Shevchenko-Bitensky K. Anxiety and depressive disorders in psoriatic disease (clinical and pathogenic, therapeutic, and aspects of life quality)

There are 257 patients with PD (94 patients of the control group with TMT and 163 patients of the group with the use of ITC, including a complex of valproic acid, NES and IP) studied in thesis, based on a comprehensive clinical psychopathology, psycho-physiological, psycho-diagnostic, psychometric and electrophysiological studies. As a result of statistical processing of the data, patients were divided into three groups with different variants of anxiety and depressive disorders: 1. Mixed anxiety and depressive reaction, related to adjustment disorder (F 43.22 - 104 patients - 40.5%); 2. Mixed anxiety and depressive disorder (F 41.2 - 75 patients - 29.2%); 3.Mixed anxiety and depressive disorders, on the background of an organic lesion of the CNS (F 06.368 - 78 patients - 30.3%). It was determined that along with the comorbidity occurring anxiety and depressive disorders in the PD are statistically significant (P <0.05) dysfunction of identity and forms of personal response, significantly worsens the quality of life of PD patients. All identified in PD comorbid anxiety and depressive disorders, self-awareness and personal response disorders (as well as skin lesions) in PASI scores are statistically significant therapeutic effect under the influence of the ITC. When TMT therapy (control group of patients) were noticed a trend towards improvement in these areas, but not statistically significant (P> 0.05).